JP2023534094A5 - - Google Patents
Info
- Publication number
- JP2023534094A5 JP2023534094A5 JP2022566136A JP2022566136A JP2023534094A5 JP 2023534094 A5 JP2023534094 A5 JP 2023534094A5 JP 2022566136 A JP2022566136 A JP 2022566136A JP 2022566136 A JP2022566136 A JP 2022566136A JP 2023534094 A5 JP2023534094 A5 JP 2023534094A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- cfrna
- target
- molecules
- detecting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063039886P | 2020-06-16 | 2020-06-16 | |
| US63/039,886 | 2020-06-16 | ||
| PCT/US2021/037668 WO2021257729A2 (en) | 2020-06-16 | 2021-06-16 | Methods for analysis of cell-free rna |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023534094A JP2023534094A (ja) | 2023-08-08 |
| JP2023534094A5 true JP2023534094A5 (enExample) | 2024-05-23 |
Family
ID=78824561
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022566136A Pending JP2023534094A (ja) | 2020-06-16 | 2021-06-16 | 無細胞ｒｎａの分析方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20210388451A1 (enExample) |
| EP (1) | EP4165206A4 (enExample) |
| JP (1) | JP2023534094A (enExample) |
| CN (1) | CN115698321A (enExample) |
| AU (1) | AU2021292521A1 (enExample) |
| CA (1) | CA3177118A1 (enExample) |
| WO (1) | WO2021257729A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024535694A (ja) * | 2021-09-10 | 2024-10-02 | グレイル インコーポレイテッド | 生体液中の標的分子の分析方法 |
| WO2023147445A2 (en) * | 2022-01-27 | 2023-08-03 | Oregon Health & Science University | Cell-free rna biomarkers for the detection of cancer or predisposition to cancer |
| GB2623570B (en) * | 2022-10-21 | 2025-07-23 | Wobble Genomics Ltd | Method and products for biomarker identification |
| CN116312800A (zh) * | 2023-03-08 | 2023-06-23 | 中山大学附属第八医院（深圳福田） | 一种基于血浆中循环rna全转录组测序的肺癌特征识别方法、装置和存储介质 |
| WO2024263972A2 (en) * | 2023-06-21 | 2024-12-26 | Burzynski Stanislaw R | Compositions comprising antineoplastons and methods of treating uncommon cancers |
| CN116825177A (zh) * | 2023-06-28 | 2023-09-29 | 北京津渡生科科技有限公司 | 基于统计学与随机森林的游离rna肝癌早筛方法及系统 |
| CN120752533A (zh) * | 2023-09-18 | 2025-10-03 | 深圳华大生命科学研究院 | 对游离rna进行组织溯源的方法及装置 |
| WO2026094720A1 (ja) * | 2024-10-28 | 2026-05-07 | アークレイ株式会社 | 性質判定モデルの生成方法、性質判定モデル、性質判定方法、性質判定装置、プログラム及び記録媒体 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150160221A1 (en) * | 2012-01-09 | 2015-06-11 | Suzhou Microdiag Biomedicine Co., Ltd | Biomarkers for breast cancer predictions and diagnoses |
| WO2016077709A1 (en) * | 2014-11-14 | 2016-05-19 | Liquid Genomics, Inc. | Use of circulating cell-free rna for diagnosis and/or monitoring cancer |
| JP2020511933A (ja) * | 2016-11-22 | 2020-04-23 | プライム ゲノミクス，インク． | 癌検出のための方法 |
| WO2018208892A1 (en) * | 2017-05-10 | 2018-11-15 | Nantomics, Llc | Circulating rna for detection, prediction, and monitoring of cancer |
| CA3095056A1 (en) * | 2018-04-13 | 2019-10-17 | Freenome Holdings, Inc. | Machine learning implementation for multi-analyte assay of biological samples |
| DK3781714T3 (da) * | 2018-04-14 | 2026-03-30 | Natera Inc | Fremgangsmåder til cancerpåvisning og -overvågning ved personlig påvisning af cirkulerende tumor-dna |
| EP4647512A2 (en) * | 2018-06-22 | 2025-11-12 | ClearNote Health, Inc. | Hydroxymethylation analysis of cell-free nucleic acid samples for assigning tissue of origin, and related methods of use |
| US20200105375A1 (en) * | 2018-09-28 | 2020-04-02 | Grail, Inc. | Models for targeted sequencing of rna |
| US11512349B2 (en) * | 2018-12-18 | 2022-11-29 | Grail, Llc | Methods for detecting disease using analysis of RNA |
-
2021
- 2021-06-16 AU AU2021292521A patent/AU2021292521A1/en not_active Abandoned
- 2021-06-16 US US17/349,734 patent/US20210388451A1/en not_active Abandoned
- 2021-06-16 CA CA3177118A patent/CA3177118A1/en active Pending
- 2021-06-16 CN CN202180039805.5A patent/CN115698321A/zh active Pending
- 2021-06-16 JP JP2022566136A patent/JP2023534094A/ja active Pending
- 2021-06-16 EP EP21826943.9A patent/EP4165206A4/en not_active Withdrawn
- 2021-06-16 WO PCT/US2021/037668 patent/WO2021257729A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Garzon et al. | Expression and prognostic impact of lncRNAs in acute myeloid leukemia | |
| Lee et al. | Incorporating deep learning and multi-omics autoencoding for analysis of lung adenocarcinoma prognostication | |
| Varghese et al. | Site-specific gene expression profiles and novel molecular prognostic factors in patients with lower gastrointestinal adenocarcinoma diffusely metastatic to liver or peritoneum | |
| Babapoor et al. | Identification of microRNAs associated with invasive and aggressive phenotype in cutaneous melanoma by next-generation sequencing | |
| JP2009523028A5 (enExample) | ||
| Liu et al. | An independent evaluation in a CRC patient cohort of microbiome 16S rRNA sequence analysis methods: OTU clustering, DADA2, and Deblur | |
| CN110656181B (zh) | 一种用于非小细胞肺癌诊断的外周血miRNA标志物 | |
| Chanudet et al. | Large‐scale genome‐wide screening of circulating microRNAs in clear cell renal cell carcinoma reveals specific signatures in late‐stage disease | |
| JP2010518811A5 (enExample) | ||
| Li et al. | Modeling microRNA-mRNA interactions using PLS regression in human colon cancer | |
| Earp et al. | Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA | |
| JP2021511057A (ja) | 結腸がんの検出および治療の方法 | |
| Nannini et al. | miRNA profiling in gastrointestinal stromal tumors: implication as diagnostic and prognostic markers | |
| Ghafouri-Fard et al. | A review on the role of ZEB1-AS1 in human disorders | |
| ES2686631T3 (es) | Determinaciones de cáncer de pulmón utilizando relaciones de miARN | |
| Tang et al. | Identifying gene modules of thyroid cancer associated with pathological stage by weighted gene co-expression network analysis | |
| Wang et al. | Tumor mutational burden related classifier is predictive of response to PD-L1 blockade in locally advanced and metastatic urothelial carcinoma | |
| Guglielmelli et al. | Small RNA sequencing uncovers new miRNAs and moRNAs differentially expressed in normal and primary myelofibrosis CD34+ cells | |
| Liu et al. | Wnt-regulated lncRNA discovery enhanced by in vivo identification and CRISPRi functional validation | |
| US20240336977A1 (en) | Microrna-regulated biomarkers and drug targets for improving diagnosis and treatment of lung or breast cancer | |
| Hemati et al. | Circular RNAs and tuberculosis infection | |
| Franzini et al. | Gene expression signatures predictive of bevacizumab/erlotinib therapeutic benefit in advanced nonsquamous non–small cell lung cancer patients (SAKK 19/05 trial) | |
| US20140148357A1 (en) | Characterizing Gastro-Intestinal Disease | |
| Pipelers et al. | A unified censored normal regression model for qPCR differential gene expression analysis | |
| Guo et al. | Tumor-infiltrating immune cells based TMEscore and related gene signature is associated with the survival of CRC patients and response to fluoropyrimidine-based chemotherapy |